Back to Directory Elizabeth Rivas Email erivas@fhi360.org Phone 1 919-321-3890 Institution FHI 360 Address FHI 360 359 Blackwell Street, Suite 200 Durham, NC 27701 USA Request an Update Affiliated Studies IMPAACT 2047: Radiant-Moms Plus DAIDS Number 39188 Research Area Tuberculosis Study Status In Development IMPAACT 2026: Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum DAIDS Number 38609 Research Area Therapeutics Study Status Closed to Accrual IMPAACT 2035/HVTN 604: Phase I/II Randomized, Placebo-Controlled Study of the Safety and Immunogenicity of VPM1002 Vaccination or BCG Revaccination against Tuberculosis in Pre-Adolescents Living with and without HIV in South Africa (LEAP) DAIDS Number 38846 Research Area Tuberculosis Study Status Withdrawn IMPAACT 2039: EXCEED DAIDS Number 38,988 Research Area Cure and Immunotherapy Study Status In Development
IMPAACT 2047: Radiant-Moms Plus DAIDS Number 39188 Research Area Tuberculosis Study Status In Development
IMPAACT 2026: Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum DAIDS Number 38609 Research Area Therapeutics Study Status Closed to Accrual
IMPAACT 2035/HVTN 604: Phase I/II Randomized, Placebo-Controlled Study of the Safety and Immunogenicity of VPM1002 Vaccination or BCG Revaccination against Tuberculosis in Pre-Adolescents Living with and without HIV in South Africa (LEAP) DAIDS Number 38846 Research Area Tuberculosis Study Status Withdrawn
IMPAACT 2039: EXCEED DAIDS Number 38,988 Research Area Cure and Immunotherapy Study Status In Development